NCT01319487已完成2 期
A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 267
- 试验地点
- 65
- 主要终点
- change from baseline of central retinal thickness as determined by logOCT
研究概览
简要总结
The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, at least 18 years of age.
- •Diagnosis of diabetes mellitus
- •Patient must be able to self administer study drug.
- •Clinically significant diabetic macular edema in at least one eye ("study eye") involving the center of the macula:
- •Mild to severe non proliferative diabetic retinopathy (Early Treatment Diabetic Retinopathy Study [ETDRS] grade between 20 and 53).
- •BCVA score ≥ 34 letters and < 80 letters in the study eye.
- •Women of childbearing potential must have a negative urine pregnancy test at Screening and be using two highly effective methods of contraception throughout the study.
- •Male patients with partners of childbearing potential must agree to use at least one highly effective method of contraception throughout the study.
排除标准
- •Ocular conditions:
- •Any ocular condition in the study eye that in the opinion of the investigator would prevent improvement in visual acuity.
- •Proliferative diabetic retinopathy in the study eye.
- •History of panretinal scatter photocoagulation(PRP)in the study eye within 4 months prior to screening, and/or anticipated need for PRP in the 3 months following randomization.
- •Active optic disc or retinal neovascularization, rubeosis iridis, active or history of choroidal neovascularization in the study eye.
- •History of pars plana vitrectomy at any time, intraocular surgery in the study eye within 90 days prior to screening.
- •History of use of intravitreal injectable or periocular depots corticosteroids (other than triamcinolone acetonide)within 3 months prior to the screening visit in the study eye.
- •Patients who have previously received triamcinolone acetonide in the study eye:
- •The intended dose for each triamcinolone acetonide injection was more than 4 mg.
- •The most recent dose was less than 3 months prior to the screening visit.
- •Any treatment-related adverse event that was seen, and in the opinion of the investigator, has the potential to worsen or reoccur with study treatment.
- •Patients who have previously received anti-VEGF therapy within 3 months prior to the screening visit in the study eye.
- •Uncontrolled glaucoma or glaucoma treated by 2 or more medications.
- •Aphakia or intraocular lens placement in the anterior chamber of the study eye.
- •Any active ocular infection; any history of recurrent or chronic infection or inflammation in the study eye.
- •History of herpetic infection in either eye.
- •History of corneal pathology/surgery
- •Contact lens use at any time during the study.
- •Systemic conditions:
- •Uncontrolled systemic disease.
- •Poorly controlled diabetes mellitus.
- •Impaired renal function
- •Poorly controlled arterial hypertension
研究组 & 干预措施
2304 Eye Drops High Dose
Experimental
2304 Eye Drops High Dose self-administered in the study eye during the treatment period
干预措施: 2304 Eye Drops High Dose (Drug)
2304 Eye Drops Low Dose
Experimental
2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
干预措施: 2304 Eye Drops Low Dose (Drug)
Placebo Eye Drops
Placebo Comparator
Placebo Eye Drops self-administered in the study eye during the treatment period
干预措施: Placebo Eye Drops (Drug)
结局指标
主要结局
change from baseline of central retinal thickness as determined by logOCT
时间窗: Week 12
次要结局
- Proportion of patients with an improvement in best corrected visual acuity (BCVA)(Week 12)
- Change in macular volume and retinal thickness from baseline to Week 12 and Week 24(Baseline, Week 12, Week 24)
研究者
研究点 (65)
Loading locations...
相似试验
已完成
2 期
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus ErythematosusLupus Erythematosus, SystemicNCT01405196Pfizer183
已完成
2 期
A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm LaborLabor, PrematurePremature BirthNCT00209326Ferring Pharmaceuticals163
已完成
2 期
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid ArthritisRheumatoid ArthritisNCT01393639Pfizer323
已完成
3 期
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsObesityNCT00563368VIVUS LLC756
已完成
2 期
Dose Range Finding Study of Fedovapagon in Men With NocturiaNocturiaNCT01656239Vantia Ltd358